Cargando…

MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody

Targeting cancer antigens by T cell-engaging bispecific antibody (BiAb) or chimeric antigen receptor T cell therapy has achieved successes in hematological cancers, but attempts to use it to fight solid cancers have been disappointing, in part due to antigen escape. MEK inhibitor had limited activit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Hongjian, Huang, Cheng, Zhang, Zongliang, Feng, Yunyu, Wang, Zeng, Tang, Xin, Zhong, Kunhong, Hu, Yating, Guo, Gang, Zhou, Liangxue, Guo, Wenhao, Xu, Jianguo, Yang, Hui, Tong, Aiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477310/ https://www.ncbi.nlm.nih.gov/pubmed/32984002 http://dx.doi.org/10.3389/fonc.2020.01527

Ejemplares similares

Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy
por: Huang, Cheng, et al.
Publicado: (2020)

Lipid Nanoparticle Delivery System for mRNA Encoding B7H3‐redirected Bispecific Antibody Displays Potent Antitumor Effects on Malignant Tumors
por: Huang, Cheng, et al.
Publicado: (2022)

Enhancing the antitumor potency of T cells redirected by bispecific antibodies
por: Chang, Chien-Hsing, et al.
Publicado: (2017)

T cell stimulation and expansion by SunTag-based clustering of anti-CD3/CD28 scFv
por: Zhong, Kunhong, et al.
Publicado: (2020)

Ipilimumab augments antitumor activity of bispecific antibody-armed T cells
por: Yano, Hiroshi, et al.
Publicado: (2014)

Influence of the bispecific antibody IgG subclass on T cell redirection
por: Kapelski, Stephanie, et al.
Publicado: (2019)

B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors
por: Zhang, Zongliang, et al.
Publicado: (2020)

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
por: Lin, Tsung-Yi, et al.
Publicado: (2021)

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2020)

Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell–Redirected Bispecific Antibodies
por: Lussana, Federico, et al.
Publicado: (2021)

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

AP-64, Encoded by C5orf46, Exhibits Antimicrobial Activity against Gram-Negative Bacteria
por: Zhong, Kunhong, et al.
Publicado: (2021)

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
por: Choi, Bryan D, et al.
Publicado: (2013)

Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma
por: Hosny, Mashhour, et al.
Publicado: (2021)

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
por: Märkl, Florian, et al.
Publicado: (2023)

T‐cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions
por: O'Neill, Chloe, et al.
Publicado: (2023)

Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies Against Extranodal Nasal Natural Killer/T Cell Lymphoma
por: Zheng, Meijun, et al.
Publicado: (2020)

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity
por: Zhang, Congcong, et al.
Publicado: (2021)

Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities
por: Wang, Guoqing, et al.
Publicado: (2022)

Engineering Immune Cells for in vivo Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies
por: Blanco, Belén, et al.
Publicado: (2020)

Bispecific Antibody Format and the Organization of Immunological Synapses in T Cell-Redirecting Strategies for Cancer Immunotherapy
por: Carrasco-Padilla, Carlos, et al.
Publicado: (2022)

Efficient and Highly Specific Gene Transfer Using Mutated Lentiviral Vectors Redirected with Bispecific Antibodies
por: Parker, Christina L., et al.
Publicado: (2020)

Bispecific Antibody Inhalation Therapy for Redirecting Stem Cells from the Lungs to Repair Heart Injury
por: Liu, Mengrui, et al.
Publicado: (2020)

Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform
por: Borrok, M. Jack, et al.
Publicado: (2022)

Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors
por: Yang, Meijia, et al.
Publicado: (2020)

Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy
por: Santich, Brian H., et al.
Publicado: (2020)

Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells
por: Rajendran, Sakthi, et al.
Publicado: (2019)

Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning
por: Haber, Lauric, et al.
Publicado: (2021)

Bispecific antibodies in multiple myeloma treatment: A journey in progress
por: Cho, Shih-Feng, et al.
Publicado: (2022)

Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis
por: Noori, Maryam, et al.
Publicado: (2023)

Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific Antibody
por: Meng, Weixu, et al.
Publicado: (2017)

Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells
por: Huckaby, Justin T, et al.
Publicado: (2021)

Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma
por: Tang, Xin, et al.
Publicado: (2021)

Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer
por: Ali, Aesha I., et al.
Publicado: (2019)

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
por: Lutz, Martina Svenja, et al.
Publicado: (2022)

Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours
por: Sano, Yuji, et al.
Publicado: (2022)

T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
por: Kamakura, Daisuke, et al.
Publicado: (2021)

Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy
por: Kobold, Sebastian, et al.
Publicado: (2018)

GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody
por: Gedeon, Patrick C., et al.
Publicado: (2020)

Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial
por: Komatsu, Shun-ichiro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hrqq3uoht20h0mrin35sjun0v4